Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

SAN DIEGO, March 28, 2021 /PRNewswire/ — Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) (“Zynerba ” or the “Company”) against certain of its officers and directors. Specifically, a class-action lawsuit pending in the…


Continue Reading

HEDGE accordingly